drugset / Trial / NCT00697086

European Study of Dronedarone in Atrial Fibrillation

NCT00697086

Phase 3 Completed 174 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy of dronedarone for the control of ventricular rate at rest and during exercise in patients with atrial fibrillation (AF) and to assess the tolerability of dronedarone in the target population.

Timeline

Start
2002-08
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronedarone Small molecule 400 mg

Indications